Clinical trials · Michigan
Neoplasms clinical trials in Michigan
We’re tracking 129 recruiting neoplasms studies with a site in Michigan — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Michigan
- NCT07412002Recruiting
End-of-life care quality for children with cancer
This trial asks bereaved parents about the quality of care their child received in the last month of life. It aims to improve how hospitals support families when a child with cancer is dying.
Grand Rapids, MichiganAges 18 years+ - NCT07365007Recruiting
Diet study to improve nerve pain after chemo
This study tests a diet program delivered online to help reduce nerve damage symptoms like numbness and tingling caused by chemotherapy. It is for cancer survivors who completed treatment and still have these symptoms.
Ann Arbor, MichiganAges 18 years+ - NCT06150157RecruitingPhase 1
Study of JNJ-88549968 for CALR-mutated blood cancers
This study tests an experimental drug called JNJ-88549968 in people with certain blood cancers (essential thrombocythemia or myelofibrosis) that have a CALR gene mutation. It may offer a new treatment option for those who haven't responded well to other therapies.
Ann Arbor, MichiganAges 18 years+ - NCT07129252RecruitingPhase 1/Phase 2
A study of CRN09682 for NET and other solid tumors
This trial tests a new drug called CRN09682 for people with neuroendocrine tumors (NETs) or other solid tumors that have grown despite treatment and show a specific marker on scans. The goal is to see if the drug is safe and works against these cancers.
Detroit, MichiganAges 18 years+ - NCT07469891RecruitingPhase 1
Study of PRT12396 for JAK2-positive blood cancers
This trial tests an experimental drug, PRT12396, for people with certain blood cancers (polycythemia vera or myelofibrosis) that have a specific JAK2 mutation. It aims to see if the drug is safe and starts to work against the disease.
Grand Rapids, MichiganAges 18 years+ - NCT06131840RecruitingPhase 1
Study of SGN-CEACAM5C for advanced solid tumors
This trial tests a new drug called SGN-CEACAM5C in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein on cancer cells to try to stop them from growing.
Grand Rapids, MichiganAges 18 years+ - NCT07213609RecruitingPhase 1/Phase 2
Study of GSK5460025 for advanced solid tumors
This trial tests a new drug, GSK5460025, alone or with other cancer treatments, for people with advanced solid tumors that have spread or cannot be removed by surgery. It may help those whose cancer has a specific genetic feature (dMMR or MSI-H) or who have not responded to standard treatments.
Detroit, MichiganAges 18 years+ - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune conditions
This Phase 1 study tests nivolumab, an immunotherapy “anti-cancer accelerator,” in people with advanced cancer who also have an autoimmune disorder. It aims to see if nivolumab can be given safely and whether it may help shrink or control cancer.
Detroit, MichiganAges 18 years+ - NCT04641247RecruitingPhase 2
Long-term niraparib follow-up for people already benefiting
This study looks at continuing niraparib for a longer time in people who already finished an earlier niraparib trial and are still benefiting. It may help understand how safe and useful long-term treatment is for you.
Grand Rapids, MichiganAges 18 years+ - NCT04858256RecruitingPhase 2
Pacritinib for relapsed or resistant T-cell blood cancers
This Phase 2 trial studies pacritinib, an oral medicine, for T-cell lymphoma/leukemia that has come back or did not respond to prior treatment. It aims to see how well pacritinib can control the cancer and improve outcomes.
Ann Arbor, MichiganAges 18 years+ - NCT05711667RecruitingPhase 3
Letermovir to prevent CMV after stem cell transplant in kids
This trial tests whether the medicine letermovir can prevent a common virus (CMV) from coming back after an allogeneic stem cell transplant in children. It may help lower the risk of CMV infection during the vulnerable period right after transplant.
Detroit, MichiganAges 2–18 - NCT05786924RecruitingPhase 1/Phase 2
Targeted cancer drug study for RAS/RAF mutation-positive tumors
This Phase 1/2 study tests S241656 (a targeted cancer medicine) in people whose cancers have certain “RAS/RAF” gene changes. It may help shrink tumors or control cancer growth, and also finds the safest dose and best way to use the drug.
Grand Rapids, MichiganAges 18 years+ - NCT05855200RecruitingPhase 3
Dostarlimab around surgery for certain untreated colon cancers
This trial studies dostarlimab given around the time of colon cancer surgery for people with untreated, resectable (operable) stage T4N0 or stage III colon cancer that has specific tumor markers. It may help shrink or eliminate the cancer before or after surgery by boosting the immune response.
Ann Arbor, MichiganAges 18 years+ - NCT06500455RecruitingPhase 3
Standard vs longer radiation for brain metastases
This trial compares the usual short course of radiation therapy (one session) to a longer course (up to 5 sessions) for people with cancer that has spread to the brain. The goal is to see if the longer course works better and causes fewer side effects.
Ann Arbor, MichiganAges 18 years+ - NCT06501040Recruiting
Learning about cancer clinical trials for interested adults
This study aims to help people learn more about cancer clinical trials and become more comfortable with the idea of joining one. It is open to adults connected to Karmanos Cancer Institute who want to learn and give their permission to participate.
Detroit, MichiganAges 21 years+ - NCT06663319RecruitingPhase 1
Study of JNJ-89402638 for metastatic colorectal and gastric cancers
This trial tests a new drug, JNJ-89402638, alone or with other treatments for people with metastatic colorectal or gastric cancer that has progressed after standard therapies. It aims to find safe and effective doses and combinations.
Grand Rapids, MichiganAges 18 years+ - NCT06914479RecruitingPhase 1
Gene therapy and valacyclovir for recurrent brain tumors in young people
This trial tests a new gene therapy that uses two special viruses and an oral antiviral drug (valacyclovir) to treat brain tumors that have come back in children and young adults. The therapy is given right after surgery to remove the tumor, with the goal of helping your immune system fight the cancer.
Ann Arbor, MichiganAges 3–39 - NCT05538130RecruitingPhase 1
Study medicine for BRAF-mutated advanced solid tumors
This Phase 1 trial studies how PF-07799544 works and what dose is safest in people with advanced cancer that has a specific genetic change called BRAF V600. You may receive it alone or with another treatment, depending on the tumor group, to see if it can treat the cancer.
Detroit, MichiganAges 16 years+ - NCT06841354RecruitingPhase 3
Sac-TMT alone or with pembrolizumab for advanced triple-negative breast cancer
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Grand Rapids, MichiganAges 18 years+ - NCT07209111RecruitingPhase 2
Testing Calderasib for advanced solid tumors with KRAS G12C mutation
This trial tests a new drug, Calderasib (MK-1084), for people with advanced solid tumors that have a specific KRAS G12C mutation and aren't getting better with standard treatments. The goal is to see if the drug can help shrink or control the cancer.
Grand Rapids, MichiganAges 18 years+ - NCT06925737RecruitingPhase 3
Study of I-DXd for metastatic prostate cancer
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with metastatic prostate cancer that has stopped responding to hormone therapy. It may help by targeting and destroying cancer cells in a different way.
Ann Arbor, MichiganAges 18 years+ - NCT06001788RecruitingPhase 1
Ziftomenib for relapsed or refractory acute myeloid leukemia
This trial tests a new drug combination called ziftomenib for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. Researchers will check how safe it is and what side effects happen.
Detroit, MichiganAges 18 years+ - NCT00900198Recruiting
Give cancer tissue samples to help future cancer research
This study collects tissue or other cancer-related samples to help researchers better understand cancer and develop better tests or treatments. You can join if you are being evaluated for or treated for cancer, and you agree to let your samples be used for research.
Ann Arbor, MichiganAges 2 months+ - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Ann Arbor, MichiganAges 18 years+
Neoplasms trials by city in Michigan
Where these studies are running in Michigan
Institutions with a site for the recruiting neoplasms studies listed above.
- University of Michigan · 8 studies
- START Midwest · 7 studies
- Henry Ford Health · 4 studies
- GSK Investigational Site · 3 studies
- Wayne State University/Karmanos Cancer Institute · 3 studies
- Cancer & Hematology Centers of Western Michigan · 2 studies
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital · 2 studies
- Brigitte Harris Cancer Pavilion
What taking part in a neoplasms study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Neoplasms trials in other states
Common questions
- Are there neoplasms clinical trials in Michigan?
- Yes. We're currently tracking 129 recruiting neoplasms studies with a site in Michigan, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a neoplasms study in Michigan?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Michigan to take part?
- Not necessarily. These studies have a site in Michigan, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a neoplasms trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New neoplasms studies open in Michigan regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.